Revolution Medicines partners Royalty Pharma on $2bn funding
Pharmaceutical Technology
JUNE 25, 2025
The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones. Sign up for our daily news round-up!
Let's personalize your content